Renergen Ltd. operates as an investment holding company, which engages in the provision of alternative and renewable energy sectors. The Virginia Gas Project comprises production rights of approximately 187,000 hectares of gas fields across Welkom, Virginia and Theunissen, in the Free State. Its segments include Tetra4, Cryovation, Renergen US and Corporate head office. Tetra4 segment explores, produces and sells LNG and is focused on producing and selling LHe. The company operates in the Gauteng Province, Free State Province and Mpumalanga Province in the town of Evander. Cryovation segment develops the Cryo-Vacc technology, which enables the safe transportation of vaccines and biologics at extremely low temperatures without the need for electrical power. Renergen US segment assists with various fund raising and business development activities of the group in the United States market.
根据最新的财务报表(Form-10K),Therapeutic Solutions International Inc 的总资产为 $0,净亏损为 $0
RGNNF 的关键财务比率是什么?
Therapeutic Solutions International Inc 的流动比率是 0,净利 margin 为 0,每股销售为 $0。
RENERGEN Ltd 的收入按细分市场或地理位置如何划分?
Therapeutic Solutions International Inc 最大收入来源是 Immune Modulation,在最近的收益报告中收入为 98,994。就地区而言, United States 是 Therapeutic Solutions International Inc 的主要市场,收入为 98,994。
RENERGEN Ltd 是否盈利?
否,根据最新的财务报表,Therapeutic Solutions International Inc 的净亏损为 $0